Tisagenlecleucel

Global Drugs for Immunotherapy Market (2022 to 2031) - Featuring Novartis, Amgen and AbbVie Among Others - ResearchAndMarkets.com

Retrieved on: 
星期一, 三月 21, 2022
Pharmaceutical, Health, Oncology, Cancer, Obesity, Cancer Research UK, Interleukin, Federal Food, Drug, and Cosmetic Act, Marketing, Immunotherapy, IVD, BMS, Pfizer, Food and Drug Administration, Vaccine, Illumina, Inc., NGS, Research, Interferon, Hospital, Tisagenlecleucel, Novartis, Gilead Sciences, Death, Bristol Myers Squibb, Food, American Cancer Society, Prevalence, Skin cancer, Immune system, Technology, Ipilimumab, Organic acid, Cancer research, Smoking, Melanoma, FD, FDA, Protein, Patient, Infection, Antibody, Pharmaceutical industry, Illumina

The drugs for immunotherapy market consist of sales of immunotherapy drugs.

Key Points: 
  • The drugs for immunotherapy market consist of sales of immunotherapy drugs.
  • The rising incidences of cancer are expected to increase the demand for immunotherapy drugs driving market growth.
  • The high cost of immunotherapy drugs is acting as a restraint on the drugs for immunotherapy market as a smaller number of patients can afford the treatment.
  • Immunotherapy drugs are expensive as drugs are made specifically for each patient and investment costs in the research and development are high.

Candel Therapeutics Appoints Seshu Tyagarajan, Ph.D., RAC, as Chief Technical and Development Officer

Retrieved on: 
星期三, 三月 2, 2022
Private Securities Litigation Reform Act, BLA, Purdue University, Patient, Â, Research, Virus, Biological engineering, Tisagenlecleucel, Roche, ImClone Systems, Eli Lilly, MS, Merck, Character, FDA, Church Avenue station (IND Culver Line), CGT, RAC, Rutgers University, Therapy, Late, SEC, Company, Joint Planning and Development Office, Cancer, Form, Immunogenic cell death, CEO, Biochemistry, HSV, Content discovery platform, Technology, Fellow of the Academy of Medical Sciences, CADL, Nasdaq, GLOBE, Pharmaceutical industry, Doctor of Philosophy, Biogen, Candel, Novartis

NEEDHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Seshu Tyagarajan Ph.D., RAC, has been named as the companys Chief Technical and Development Officer.

Key Points: 
  • NEEDHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Seshu Tyagarajan Ph.D., RAC, has been named as the companys Chief Technical and Development Officer.
  • Dr. Tyagarajan brings to Candel over two decades of technical, manufacturing and development experience in biologics and cell and gene therapies (CGT).
  • Dr. Tyagarajan joins the company from Novartis, where she was most recently Executive Director and Global Head, Late Stage CMC Strategy for CGT.
  • Dr. Tyagarajan holds a Ph.D. in Chemical and Biochemical Engineering from Rutgers University and an MS in Bioengineering from Purdue University.

IMV to Host a Webcast to Highlight its Immune-Educating DPX® Platform

Retrieved on: 
星期四, 二月 17, 2022
Science, Other Science, Biotechnology, Research, Oncology, General Health, Health, Clinical Trials, Eli Lilly, Webcast, University, Fred Hutchinson Cancer Research Center, Company, Research, CART, SEDAR, EDGAR, Research and development, Immunotherapy, Forward-looking statement, Vaccine, Immune system, CTL019, Nasdaq, Development, KOL, Leadership, Terminology, Technology, Novartis, Bladder cancer, LinkedIn, Doctor of Philosophy, Twitter, Mission statement, DLBCL, Eastern Time Zone, Infection, Survivin, DPX, Penn, TSX, IMV, Organization, Pharmaceutical industry, Tisagenlecleucel

The IMV team will describe the DPX delivery platform technology and its differentiated immune-educating capabilities, highlighting key advantages demonstrated in both clinical and preclinical studies including its favorable safety profile.

Key Points: 
  • The IMV team will describe the DPX delivery platform technology and its differentiated immune-educating capabilities, highlighting key advantages demonstrated in both clinical and preclinical studies including its favorable safety profile.
  • IMV management will also provide an update on the Companys clinical programs and discuss key expected milestones in 2022.
  • IMV Inc. is a clinical-stage immuno-oncology company advancing a portfolio of therapies based on the Companys immune-educating platform: the DPX technology.
  • IMV is also developing a second immunotherapy leveraging the DPX immune delivery platform, DPX-SurMAGE.

Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer

Retrieved on: 
星期三, 一月 26, 2022
U.S. Securities and Exchange Commission, Biochemistry, Growth, Nasdaq, Escola Superior de Propaganda e Marketing, Commercial, TCR, Novartis, PSLRA, SEC, Private Securities Litigation Reform Act, University, VP, NVS, Bluebird bio, Security (finance), Tisagenlecleucel, BLA, Cancer, Marketing, Engineering, MBA, Multiple myeloma, NYSE, ADAP, GLOBE, Pharmaceutical industry, Pharmacy, Cintia

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022.

Key Points: 
  • PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022.
  • Her fresh perspective and leadership abilities will support our continued growth in our mission to design and develop cell therapies for people with cancer, said Adrian Rawcliffe, Adaptimmunes Chief Executive Officer.
  • Most recently, Cintia served as the Head of Commercial at 2Seventy Bio (Nasdaq:TSVT) and as SVP Commercial Oncology and US General Manager, leading the launch of the first cell therapy product in multiple myeloma, Abecma (idecabtagene vicleucel), for bluebird bio (Nasdaq:BLUE).
  • Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer.

William “Bill” Conkling to assume the role of Chief Executive Officer as of February 1, 2022

Retrieved on: 
星期五, 一月 21, 2022
Molecule, Research, University, Private Securities Litigation Reform Act, SEC, NYSE, RFL, Public health, Heart failure, Director, Cancer, Marketing, Bristol Myers Squibb, ACS, Tisagenlecleucel, Publication, COVID-19, MBA, Safety, Society, Company, Failure, Annual report, Commercial Operating System (COS), Patient, Fordham University, Union for International Cancer Control, Ewing, Rhône-Poulenc, Leadership, BMS, Ownership, Therapy, Acquisition, GLOBE, Drug discovery, American Chemical Society, Fibrosis, Board, Pharmaceutical industry, Immunomedics, Sacituzumab govitecan, Sanofi, Business

William (Bill) Conkling will remain with the Company and assume the responsibilities of Chief Executive Officer from Ameet Mallik as of February 1, 2022.

Key Points: 
  • William (Bill) Conkling will remain with the Company and assume the responsibilities of Chief Executive Officer from Ameet Mallik as of February 1, 2022.
  • Bill Conklinghas over 20 years of experience specializing in the development and commercialization of novel cancer therapeutics and currently serves as Rafaels Chief Commercial and Business Officer.
  • Mimi Huizinga, Chief Medical Officer, will be leaving the company as of January 31, 2022, to pursue other opportunities.
  • I am very pleased that Bill will be taking on the role as Chief Executive Officer.

2021 Research & Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy - ResearchAndMarkets.com

Retrieved on: 
星期五, 十二月 17, 2021
Pharmaceutical, Health, Clinical Trials, Medical Devices, Novartis, FDA, B-cell lymphoma, Follicular lymphoma, MCL, Adult, Kite Pharma, Industry, Primary central nervous system lymphoma, AstraZeneca, CAGR, Canadian Aviation Regulations, Patient, Multiple myeloma, DLBCL, Acute lymphoblastic leukemia, Bristol Myers Squibb, CAR, ALL, CTL019, Brexucabtagene autoleucel, Gilead Sciences, Vaccine, Pet, Pharmaceutical industry, Idecabtagene vicleucel, Tisagenlecleucel

The "Current Research & Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Current Research & Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy" report has been added to ResearchAndMarkets.com's offering.
  • The global market for chimeric antigen receptor (CAR) T-cell therapy is estimated to grow from $1.5 billion in 2021 to reach $7.6 billion by 2026, at a compound annual growth rate (CAGR) of 39.1% during 2021-2026.
  • The Asia-Pacific market for CAR T-cell therapy is estimated to grow from $228.9 million in 2021 to reach $2.1 billion by 2026, at a CAGR of 56.0% during 2021-2026.
  • There are five chimeric antigen receptor (CAR) T-cell therapies currently approved by the U.S. FDA.

LUMICKS Welcomes World-Renowned Scientists and Business Executives to Scientific Advisory Board

Retrieved on: 
星期三, 十二月 15, 2021
Molecule, BLA, CRISPR, MIT, HSPC, United States Air Force Scientific Advisory Board, Immunology, History, Quality control, Biology, Algorithm, Doctor of Philosophy, Foundation Medicine, Genomics, Kite Pharma, Tulane University, Hertz, NDSEG, Science, National, Immunotherapy, Mustang Bio, TCR, Broad Institute, Tisagenlecleucel, Physics, MAA, Research, Harvard College, Novartis, Danaher, R, DNA, Associate Director of National Intelligence and Chief Information Officer, Mathematics, Molecular biology, National Cancer Institute, Louisiana State University, Gene, Pharmaceutical industry, Management, Cell, Microbiology

He brings valuable insight in gene therapy, immunotherapy, oncology, CAR-T cell therapies, and T-cell therapies to the LUMICKS Board.

Key Points: 
  • He brings valuable insight in gene therapy, immunotherapy, oncology, CAR-T cell therapies, and T-cell therapies to the LUMICKS Board.
  • He has a demonstrated history of scaling companies in smart and strategic ways, and LUMICKS is eager to leverage both his scientific and business background.
  • We're proud to welcome both of these exceptional industry professionals to the LUMICKS Scientific Advisory Board."
  • LUMICKS' C-Trap Optical Tweezers Fluorescence & Label-free Microscopy, allows scientists to analyze complex biological processes in real-time.

LUMICKS Welcomes World-Renowned Scientists and Business Executives to Scientific Advisory Board

Retrieved on: 
星期三, 十二月 15, 2021
Molecule, BLA, CRISPR, MIT, HSPC, United States Air Force Scientific Advisory Board, Immunology, History, Quality control, Biology, Algorithm, Doctor of Philosophy, Foundation Medicine, Genomics, Kite Pharma, Tulane University, Hertz, NDSEG, Science, National, Immunotherapy, Mustang Bio, TCR, Broad Institute, Tisagenlecleucel, Physics, MAA, Research, Harvard College, Novartis, Danaher, R, DNA, Associate Director of National Intelligence and Chief Information Officer, Mathematics, Molecular biology, National Cancer Institute, Louisiana State University, Gene, Pharmaceutical industry, Management, Cell, Microbiology

He brings valuable insight in gene therapy, immunotherapy, oncology, CAR-T cell therapies, and T-cell therapies to the LUMICKS Board.

Key Points: 
  • He brings valuable insight in gene therapy, immunotherapy, oncology, CAR-T cell therapies, and T-cell therapies to the LUMICKS Board.
  • He has a demonstrated history of scaling companies in smart and strategic ways, and LUMICKS is eager to leverage both his scientific and business background.
  • We're proud to welcome both of these exceptional industry professionals to the LUMICKS Scientific Advisory Board."
  • LUMICKS' C-Trap Optical Tweezers Fluorescence & Label-free Microscopy, allows scientists to analyze complex biological processes in real-time.

Cancer is a Key Focus in Cell and Gene Therapy Research

Retrieved on: 
星期四, 十月 7, 2021
Knowledge, Lists of diseases, Brain, Degenerative disease, Ovarian cancer, Industry, Breast, Tisagenlecleucel, Biotechnology, NHL, Cell, Non-Hodgkin lymphoma, Acute lymphoblastic leukemia, GBM, Gilead, Blood, Growth, Cancer, Knowledge-centered support, Population, Prostate, Glioblastoma, Lung, FDA, Medicine, Gene, Multiple myeloma, Neoplasm, IVD, Pancreatic cancer, Technology, Colorectal cancer, Tumors of the hematopoietic and lymphoid tissues, Novartis, ALL, Pharmaceutical industry, Vaccine, Medical imaging

"Globally, cell and gene therapy products are transforming the treatment of cancers and genetic diseases," said Bruce Carlson, publisher for Kalorama Information.

Key Points: 
  • "Globally, cell and gene therapy products are transforming the treatment of cancers and genetic diseases," said Bruce Carlson, publisher for Kalorama Information.
  • Among the expanding areas of focus for cell and gene therapies, oncology remains one of the most intriguing and notable.
  • Cell therapy has been used for years for blood transfusions and hematopoietic stem cell transplants.
  • The CAR-T market will overshadow the cell immunotherapy, gene therapy and other cell therapy markets.

Global T-Cell Therapy Market Outlook to 2027, Featuring Profiles of Key Players including Novartis AG, Amgen, Celgene Corporation, Pfizer Inc., CR2 Therapeutics Inc and Gilead Sciences Inc - ResearchAndMarkets.com

Retrieved on: 
星期四, 十月 7, 2021
Biotechnology, Pharmaceutical, Health, Lymphocyte, Market, Center, Incidence, Merck Group, Novartis, Cytokine release syndrome, Pfizer, Adult, Food and Drug Administration, Tisagenlecleucel, Celgene, Lists of diseases, TCR, TIL, Preventive healthcare, Lymphatic system, CAR, Growth, Key, Cancer, Seizure, CRS, Hallucination, Delirium, Coma, CDC, Hospital, National Cancer Research Institute, Centers for Disease Control and Prevention, Asia, Cancer Research UK, Neoplasm, Modality, Trade, Patient, Disease, Gilead Sciences, Vaccine, Pharmaceutical industry, Agriculture, Landscape maintenance

Moreover, the development of new & effective therapy options to cure symptoms of the disease is another prominent factor accelerating the growth of global T-cell therapy market.

Key Points: 
  • Moreover, the development of new & effective therapy options to cure symptoms of the disease is another prominent factor accelerating the growth of global T-cell therapy market.
  • In addition, the increase in government initiatives for improving health care infrastructure & promoting research for cell therapy in cancer is supporting the growth of global T-cell therapy market.
  • These are major restraining factors which expected to hamper the global T-cell therapy market over the forecast period.
  • Key Players operating in the global T-cell therapy market is include Novartis AG, Amgen, Celgene Corporation, Pfizer Inc., Fate Therapeutics, Bluebird Bio Inc., TCR2 Therapeutics Inc, Sorrento Therapeutics, Gilead Sciences Inc., Merck KGaA, etc.